Product Overview
The AAV1 ELISA Control consists of fully assembled, empty AAV1 capsids. It represents the serotype-specific conformational epitopes and is therefore a reliable positive control in detection and quantification assays based on AAV antibodies detecting the conformational epitopes, such as ELISA.
Alternative Names
AAV; AAV1; AAV 1; Adeno-associated virus; Adeno-associated virus 1; Adeno-associated virus type 1
Concentration
1.2E+09 – 2.0E+09 capsids/ml after reconstitution in 500 μl ASSB 1x (please find the lot-specific concentration on the CoA and on the vial)
Reconstitution
Reconstitute in 500 μl ASSB 1x, incubate 5 min at RT and mix by rolling 5 min. Avoid vortexing! The final solution contains stabilizing protein, phenol red and ASSB 1x buffer.
Introduction
Adeno-Associated Virus (AAV) is a nonpathogenic virus species that belongs to the Parvoviridae family. AAV is classified as small (25nm) and contains a single-stranded nonenveloped DNA genome. Infection with AAV occurs only with the help of other viruses, either herpesvirus or adenovirus (hence adeno-associated virus), causing only a very mild immune response in humans. There are twelve serotypes of human AAV but the number of nonhuman AAVs exceeds 100. AAV2 is the only mammalian DNA virus that is known to integrate in a specific site of the genome.
Keywords
AAV; AAV1; AAV 1; Adeno-associated virus; Adeno-associated virus 1; Adeno-associated virus type 1
Citations
Have you cited DAGC255 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Trabelsi, K; Kamen, A; et al. Development of a vectored vaccine against Hepatitis E virus. VACCINE 32:2808-2811(2014).
Gabriel, R; Kutschera, I; et al. Linear Amplification Mediated PCR - Localization of Genetic Elements and Characterization of Unknown Flanking DNA. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS :-(2014).